Is METS-IR a novel score to evaluate insulin sensitivity?
The Metabolic Score for Insulin Resistance (METS-IR) is a metabolic index developed with the aim to quantify peripheral insulin sensitivity in humans; it was first [...]
Is Ketoanalogue good for kidney and delay Dialysis?
Ketoanalogues of amino acids (KAs) are nitrogen-free analogs of essential amino acids. Studies have demonstrated that the benefits of ketoanalogues [...]
What hypoglycemic drugs can be used in patient with chronic renal disease (CKD)?
The table shows a summary correlating the therapeutic class and the dose adjustment based on creatinine clearance. Class and Medication [...]
Why does diabetic wound delay in healing?
Impaired wound healing in Diabetes is triggered by hyperglycemia, chronic inflammation, micro- and macro-circulatory dysfunction, hypoxia, autonomic and sensory neuropathy, and impaired neuropeptide signaling
Why Does Diabetes Cause Weight Loss?
When there isn’t enough insulin or cells stop responding to insulin, too much blood sugar stays in the bloodstream. When glucose doesn’t [...]
Why Does Diabetes Make You Feel So Tired?
Fatigue in people with diabetes may be caused by a variety of lifestyle, nutritional, medical, psychological, glycemic/diabetes-related, endocrine, and iatrogenic factors.
Metformin-insulin versus metformin-sulfonylurea combination therapies in type 2 diabetes
High proportion of patients who received metformin-sulfonylurea achieved target HbA1c level and had less composite cardiovascular outcomes compared to those [...]
What is the efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes?
Using individual patient data (IPD) and meta-regression methodology, researchers sought to indirectly compare the effectiveness of once-weekly (OW) semaglutide 1 mg vs once-daily (OD) empagliflozin 25 mg in patients with type 2 diabetes (T2D) inadequately controlled on metformin monotherapy. IPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) have been involved. Findings revealed that baseline features were comparable between OW semaglutide (n = 995) and empagliflozin (n = 410). According to this indirect comparison, OW semaglutide 1 mg gives superior declines in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy. Conclusions This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin [...]
What is Triglyceride glucose (TyG) index?
The TyG index is a good discriminant of Metabolic Syndrome and is a surrogate marker of insulin resistance. The TyG [...]
What Is The Difference Between Sulfonylureas And Meglitinides?
Sulfonylureas and Meglitinides are oral hypoglycemic drugs directly stimulate release of insulin from pancreatic beta cells. Meglitinides act on the same [...]
